CLEARMIND MEDICINE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.14 USD | -0.87% |
|
-5.00% | -59.43% |
Valuation
| Fiscal Period: October | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 22.25 | 10.43 | 1.784 |
| Enterprise Value (EV) 2 | 17.65 | 10.04 | -3.73 |
| P/E ratio | -4.23 x | -1.09 x | -0.09 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | - |
| EV / Revenue | - | - | - |
| EV / EBITDA | -4,804,206 x | -1,180,698 x | 593,760 x |
| EV / FCF | -11.1 x | -8.4 x | 6.13 x |
| FCF Yield | -8.97% | -11.9% | 16.3% |
| Price to Book | 4.63 x | -6.91 x | 2.26 x |
| Nbr of stocks (in thousands) | 41.7 | 44 | 488 |
| Reference price 3 | 533.6 | 237.0 | 3.657 |
| Announcement Date | 2/28/22 | 1/31/23 | 1/29/24 |
1USD in Million2CAD in Million3USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: October | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA | - | - | - | -3.674 | -8.502 | -6.281 |
| EBIT 1 | -0.2174 | -0.086 | -0.2086 | -3.866 | -8.533 | -6.303 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -0.1945 | -0.1053 | -0.2332 | -3.899 | -9.37 | -8.603 |
| Net income 1 | -0.1945 | -0.1053 | -0.2332 | -3.899 | -9.411 | -8.621 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -18.05 | -8.537 | -12.86 | -126.2 | -217.2 | -42.58 |
| Free Cash Flow 1 | -0.1781 | -0.0215 | -0.1716 | -1.583 | -1.195 | -0.6085 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 2/25/19 | 2/28/20 | 3/1/21 | 2/28/22 | 1/31/23 | 1/29/24 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: October | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 0.07 | 0 | 0.33 | 4.6 | 0.39 | 5.51 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -0.18 | -0.02 | -0.17 | -1.58 | -1.2 | -0.61 |
| ROE (net income / shareholders' equity) | -129% | -56.5% | -73.7% | -147% | -572% | 14,072% |
| ROA (Net income/ Total Assets) | -72.3% | -25.3% | -37.7% | -85.2% | -170% | -116% |
| Assets 1 | 0.269 | 0.4163 | 0.6181 | 4.577 | 5.547 | 7.418 |
| Book Value Per Share 2 | 19.40 | 10.80 | 23.40 | 115.0 | -34.30 | 1.620 |
| Cash Flow per Share 2 | 5.980 | 0.0600 | 15.40 | 110.0 | 4.000 | 8.940 |
| Capex 1 | 0.13 | 0.01 | 0.01 | 0.03 | 0.01 | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 2/25/19 | 2/28/20 | 3/1/21 | 2/28/22 | 1/31/23 | 1/29/24 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -59.43% | 3.72M | |
| +54.05% | 58.71B | |
| -2.02% | 41.31B | |
| +36.39% | 39.2B | |
| -10.22% | 27.4B | |
| +13.42% | 26.55B | |
| -21.60% | 18.98B | |
| +2.89% | 12.51B | |
| +22.40% | 11.94B | |
| +27.49% | 12.08B |
- Stock Market
- Equities
- CMND Stock
- Financials Clearmind Medicine Inc.
